Experts said millions of people across the country are prescribed a medicine for moderate to severe acute pain each year, so ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

The FDA has approved Vertex Pharmaceuticals’ Journavx, a new pain medication designed to reduce the risk of addiction and overdose associated with opioids. Intended for short-term pain after surgeries ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...